StockNews.AI
LEXX
StockNews.AI
10 days

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

1. Lexaria's ongoing Phase 1b study is assessing diabetes treatment and weight loss. 2. Study Arm 5 aims to enhance its previously successful formulation.

2 mins saved
Full Article

FAQ

Why Bullish?

Positive study outcomes can attract investor interest, similar to other clinical trials boosting stock prices.

How important is it?

The progress of clinical studies typically influences biotech stock prices significantly based on future potential.

Why Long Term?

Results could influence market perception and investor confidence over time as the study progresses.

Related Companies

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 to evaluate performance of its DehydraTECH-tirzepatide formulation, pursuant to the positive findings it previously achieved and released for Human Pilot Study #3 (GLP-1-H24-3).

Related News